| Literature DB >> 33213373 |
Leonn Mendes Soares Pereira1, Max Willy da Silva Madureira1, Renata Bezerra Hermes de Castro2, Isabella Nogueira Abreu1, Simone Regina Souza da Silva Conde3, Sâmia Demachki3, Maisa Silva de Sousa4, Maria Alice Freitas Queiroz1, Andrea Nazaré M Rangel da Silva1, Sandra Souza Lima1, Marluísa de Oliveira Guimarães Ishak1, Ricardo Ishak1, Antonio Carlos Rosário Vallinoto5.
Abstract
BACKGROUND: The forkhead box protein 3 (FOXP3) transcription factor is one of the main markers of immunological suppression in different pathological profiles, and the presence of polymorphic variants may alter the gene expression of this factor. Despite descriptions of an association between the presence of the rs2232365 polymorphism and chronic diseases, the role of the sex variant in this context has not yet been elucidated, as the FOXP3 gene is located on the human sex chromosome X.Entities:
Keywords: Chronic viral diseases; FOXP3; Polymorphism; Sex
Year: 2020 PMID: 33213373 PMCID: PMC7678194 DOI: 10.1186/s12865-020-00387-4
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Fig. 1Biological implications of the rs2232365 polymorphism: Gene expression graph containing normalized FOXP3 expression data by genotype of the rs2232365 polymorphism in whole blood and arterial tissue (GText portal). The numbers subscribed to the genotypes correspond to the total of samples collected
Association of sex and allele frequency of the rs2232365 polymorphism in patients with chronic diseases, stratified according to the clinical-pathological profile
| Sex | Alleles (rs2232365) | Alleles (rs2232365) | Multiple logistic regression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Female (323) | Male (373) | Statistic | T | C | Statistic | T | C | Statistic | ||
| 349 (54.03) | 297 (45.98) | – | 188 (50.40) | 185 (49.60) | – | |||||
| CVLD | 39 (12.07) | 62 (16.62) | 0.07 | 39 (50.00) | 39 (50.00) | 0.47 | 31 (50.00) | 31 (50.00) | 0.55 | NS |
| HTLV-1 | 44 (13.62) | 23 (06.16) | 0.03 1.91 (1.10–3.33) | 52 (59.09) | 36 (40.91) | 0.62 | 7 (33.33) | 16 (66.67) | 0.05 0.36 (0.14–0.92) | 2.11 (1.18–3.75) 0.43 (0.20–0.95) |
| CAD | 91 (28.17) | 139 (37.27) | 0.02 1.53 (1.08–2.16) | 93 (51.10) | 89 (48.90) | 0.41 | 68 (48.92) | 71 (51.08) | 0.35 | 1.44 (0.95–2.19) |
| CG | 149 (46.13) | 149 (39.95) | 165 (55.40) | 133 (44.63) | 82 (54.31) | 67 (45.70) | ||||
| A0-A1 | 24 (61.54) | 43 (69.35) | 0.52 | 24 (50.00) | 24 (50.00) | 1.0 | 20 (57.90) | 23 (53.49) | 0.58 | |
| A2-A3 | 15 (38.46) | 19 (30.65) | 15 (50.00) | 15 (50.00) | 11 (46.51) | 8 (42.11) | ||||
| F0-F1 | 20 (51.28) | 29 (46.77) | 0.82 | 20 (50.00) | 20 (50.00) | 1.0 | 10 (34.48) | 19 (65.52) | 0.05 4.18 (1.13–15.4) | 1.11 (0.43–2.90) |
| F2 | 8 (20.51) | 17 (27.42) | 8 (50.00) | 8 (50.00) | 10 (58.82) | 7 (41.18) | ||||
| F3-F4 | 11 (28.21) | 16 (25.81) | 11 (50.00) | 11 (50.00) | 11 (68.75) | 5 (31.25) | ||||
| Asymptomatic | 27 (61.36) | 13 (61.90) | 1.0 | 32 (59.26) | 22 (40.74) | 0.86 | 4 (30.77) | 9 (69.23) | 0.87 | |
| HAM/TSP | 17 (38.64) | 8 (38.10) | 20 (58.82) | 14 (41.18) | 3 (37.50) | 5 (62.50) | ||||
| | 78 (85.71) | 121 (87.05) | 0.84 | 80 (86.02) | 74 (85.06) | 1.0 | 60 (88.24) | 61 (85.92) | 0.80 | |
| | 13 (14.29) | 18 (12.95) | 13 (13.98) | 13 (14.94) | 8 (11.76) | 10 (14.08) | ||||
| | 55 (70.51) | 82 (67.77) | 0.74 | 58 (70.73) | 56 (66.67) | 0.99 | 43 (71.67) | 39 (63.93) | 0.50 | |
| | 3 (03.85) | 3 (02.48) | 2 (02.44) | 2 (02.38) | 2 (03.33) | 1 (01.64) | ||||
| Coinfection | 20 (25.64) | 36 (29.75) | 22 (26.83) | 20 (23.81) | 15 (25.00) | 21 (34.43) | ||||
CVLD Chronic Viral Liver Diseases
CAD Coronary Artery Disease
CG Control Group
x2 test. Odds ratio (Confidence interval - 95%)
*0.05 ≥ p ≥ 0.01
**0.01 ≥ p ≥ 0.001
Fig. 2Association of the rs2232365 polymorphism with biomarkers of the pathologies: In men with chronic viral liver diseases and advanced fibrosis, the viral load was higher in patients with the allele T (a); the ratio of transaminases (AST/ALT) was higher in men, however, with no differences between alleles (b); the level of GGT fluctuated between genotypes/sexes (c). In men infected with HTLV-1, the proviral load (d), T CD4+ lymphocytes (e) and the level of IL-8 (f) were low in allele T carriers; the level of IL-10 was biased lower in patients with the allele T (g), but without statistical significance. (h) In CAD patients, CRP levels were statistically similar between genotypes/sexes
Calculation of the false-positive report probability (FPRP) for the risk associations of sex and rs2232365 polymorphism to chronic diseases and their clinical and pathological profiles
| Associations | OR (IC 95%) | p | Statistical power | Prior probability | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.1 | 0.01 | 0.001 | 0.0001 | 0.00001 | ||||
| HTLV-1: | |||||||||
| Female vs Male | 1.91 (1.10–3.33) | 0.03 | 0.1971 | 0.2913 | 0.5331 | 0.9113 | 0.9913 | 0.9990 | 0.9999 |
| CAD: | |||||||||
| Female vs Male | 1.53 (1.08–2.16) | 0.02 | 0.4552 | 0.1101 | 0.2557 | 0.7558 | 0.9717 | 0.9968 | 0.9997 |
| HTLV-1: | |||||||||
| (Males) T vs C | 0.36 (0.14–0.92) | 0.05 | 0.0990 | 0.5441 | 0.7683 | 0.9676 | 0.9970 | 0.9997 | 1.0000 |
| CVLD (F0-F1): | |||||||||
| (Males) T vs C | 4.18 (1.13–15.4) | 0.05 | 0.0617 | 0.6480 | 0.8364 | 0.9787 | 0.9980 | 0.9997 | 0.9999 |
| HTLV-1: | |||||||||
| Sex (Female vs Male) | 2.11 (1.18–3.75) | 0.02 | 0.1224 | 0.2432 | 0.4717 | 0.8893 | 0.9889 | 0.9986 | 0.9999 |
| (Males) T vs C | 0.43 (0.20–0.95) | 0.04 | 0.1391 | 0.4885 | 0.7262 | 0.9598 | 0.9962 | 0.9996 | 0.9999 |
| CAD: | |||||||||
| Sex (Female vs Male) | 1.44 (0.95–2.19) | 0.02 | 0.5757 | 0.3556 | 0.6052 | 0.9324 | 0.9935 | 0.9993 | 0.9999 |
| CVLD (F0-F1): | |||||||||
| (Males) T vs C | 1.11 (0.43–2.90) | 0.05 | 0.7306 | 0.8037 | 0.9192 | 0.9903 | 0.9991 | 0.9999 | 0.9999 |
CVLD Chronic Viral Liver Diseases
CAD Coronary Artery Disease